Abstract:Background: Osteoporosis (OP) is an age-related bone disease that has emerged as a worldwide public health concern due to its increasing incidence and high disability rate. Tanshinol [D (+) β-3,4-dihydroxyphenyl lactic acid, TS], a water-soluble component extracted from Salvia miltiorrhiza, has proven to be effective in attenuating OP in vitro and in vivo . However, there is insufficient evidence to support its clinical application. Objective: This meta-analysis aimed to investigate available OP animal model studies to demonstrate the antiosteoporosis effects of TS in a systematic manner. Methods: Electronic searches of related studies were conducted in the following databases: EMBASE, PubMed, Web of Science, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese VIP Database, Chinese Biomedical Literature Database, and Wanfang. The retrieval date was January 2022, and there were no time or language restrictions. The CAMARADES 10-item quality checklist was utilized to test the risk of potential bias for each study, and modifications were performed accordingly. The primary outcome was bone mineral density (BMD, which included the femur and lumbar spine); and secondary outcomes were parameters for trabecular bone such as bone volume over total volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), conditions of the femur (including bone maximum load and bone elastic load), and markers of bone metabolism (serum osteocalcin, S-OCN). Results: A total of nine studies including 176 rats were chosen for this analysis. Egger's test revealed the presence of publication bias in various studies regarding the primary outcome. According to this systematic review, TS significantly increased the BMD of the femur (BMD-femur) ( SMD = 4.40; 95% CI = 1.61 to 7.19; p = 0.002, I 2 = 94.6%), BMD of the lumbar spine (BMD-lumbar) (SMD = 6.390; 95% CI = 2.036 to 10.744; p = 0.004, I 2 = 95.9%), BV/TV (SMD = 0.790; 95% CI = 0.376 to 1.204; p = 0.000, I 2 = 10.8), Tb.N (SMD = 0.690; 95% CI = 0.309 to 1.071; p = 0.000, I 2 = 12%), Tb.Th (SMD = 0.772; 95% CI = 0.410 to 1.134; p = 0.000, I 2 = 32.2%), and S-OCN (SMD = 3.13; 95% CI = 0.617 to 5.65; p = 0.015, I 2 = 92.3%), while the Tb.Sp level was markedly decreased in OP models in comparison to the controls (SMD = −0.822; 95% CI = −1.207 to −0.437; p = 0.000, I 2 = 0%). Moreover, TS treatment was associated with a significant improvement of the bone biomechanical indicators, including bone maximum load (SMD = 0.912; 95% CI = 0.370 to 1.455; p = 0.001, I 2 = 40%) and elasticity load (SM D = 0.821; 95% CI = 0.290 to 1.351; p = 0.002, I 2 = 0%). Conclusion: Collectively, our findings suggest that TS can improve BMD, bone microarchitecture, bone biomechanics, and S-OCN expression in rats, implying that it could be used clinically in the future. Systematic Review Registration: https://inplasy.com/inplasy-2022-3-0053/, identifier [INPLASY202230053].

Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways

Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-κB, ERK and NFATc1 signaling pathways

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NK-κβ/ERK/p38 signaling pathways

Tectoridin Inhibits Osteoclastogenesis and Bone Loss in a Murine Model of Ovariectomy-Induced Osteoporosis

Tanshinone Ameliorates Glucocorticoid-Induced Bone Loss via Activation of AKT1 Signaling Pathway

Tanshinone Ameliorates Glucocorticoid-Induced Bone Loss <i>via</i> Activation of AKT1 Signaling Pathway

Notopterol Attenuates Estrogen Deficiency-Induced Osteoporosis <i>via</i> Repressing RANKL Signaling and Reactive Oxygen Species

A Novel Anti-Osteoporotic Agent That Protects Against Postmenopausal Bone Loss by Regulating Bone Formation and Bone Resorption.

Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.

Astilbin Prevents Bone Loss in Ovariectomized Mice Through the Inhibition of RANKL‐induced Osteoclastogenesis

Virtual Screening Identified Natural Keap1-Nrf2 PPI Inhibitor Alleviates Inflammatory Osteoporosis Through Nrf2-mir214-Traf3 Axis.

Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway

Antiosteoporosis effect of tanshinol in osteoporosis animal models: A systematic review and meta-analysis

Tanshinol Attenuates the Deleterious Effects of Oxidative Stress on Osteoblastic Differentiation Via Wnt/FoxO3a Signaling

Tetrandrine Attenuates Cartilage Degeneration, Osteoclast Proliferation, and Macrophage Transformation through Inhibiting P65 Phosphorylation in Ovariectomy-induced Osteoporosis

L‐tetrahydropalmatine Suppresses Osteoclastogenesis in Vivo and in Vitro Via Blocking RANK‐TRAF6 Interactions and Inhibiting NF‐κB and MAPK Pathways

Cryptotanshinone Inhibits RANKL‐induced Osteoclastogenesis by Regulating ERK and NF‐κB Signaling Pathways